MwanzoCUP • FRA
add
Chugai Pharmaceutical Co Ltd
Bei iliyotangulia
€ 51.30
Bei za mwaka
€ 33.02 - € 56.26
Thamani ya kampuni katika soko
15.89T JPY
Wastani wa hisa zilizouzwa
76.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
TYO
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (JPY) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 343.50B | 13.71% |
Matumizi ya uendeshaji wa biashara | 87.00B | 3.12% |
Mapato halisi | 128.40B | 40.24% |
Kiwango cha faida halisi | 37.38 | 23.33% |
Mapato kwa kila hisa | — | — |
EBITDA | 194.34B | 26.30% |
Asilimia ya kodi ya mapato | 24.43% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (JPY) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 979.70B | -1.67% |
Jumla ya mali | 2.47T | 11.78% |
Jumla ya dhima | 442.86B | 44.31% |
Jumla ya hisa | 2.03T | — |
hisa zilizosalia | 1.65B | — |
Uwiano wa bei na thamani | 0.04 | — |
Faida inayotokana na mali | 18.15% | — |
Faida inayotokana mtaji | 21.57% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (JPY) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 128.40B | 40.24% |
Pesa kutokana na shughuli | 129.11B | -15.28% |
Pesa kutokana na uwekezaji | -161.72B | -856.78% |
Pesa kutokana na ufadhili | -2.25B | -10.98% |
Mabadiliko halisi ya pesa taslimu | -29.83B | -121.89% |
Mtiririko huru wa pesa | 119.43B | -27.99% |
Kuhusu
Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
10 Mac 1925
Tovuti
Wafanyakazi
5,026
